Goldman Sachs’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-418,302
| Closed | -$72M | – | 6906 |
|
|
2021
Q3 | $72M | Buy |
418,302
+300,878
| +256% | +$39.4M | 0.02% | 973 |
|
|
2021
Q2 | $14.7M | Sell |
117,424
-239,613
| -67% | -$30.2M | ﹤0.01% | 2329 |
|
|
2021
Q1 | $48.4M | Buy |
357,037
+39,710
| +13% | +$5.13M | 0.01% | 1189 |
|
|
2020
Q4 | $40.6M | Sell |
317,327
-163,415
| -34% | -$19.2M | 0.01% | 1287 |
|
|
2020
Q3 | $54.1M | Sell |
480,742
-12,269
| -2% | -$1.22M | 0.02% | 932 |
|
|
2020
Q2 | $47M | Buy |
493,011
+59,141
| +14% | +$5.7M | 0.01% | 1003 |
|
|
2020
Q1 | $39M | Buy |
433,870
+113,865
| +36% | +$8.85M | 0.01% | 1039 |
|
|
2019
Q4 | $17M | Sell |
320,005
-76,537
| -19% | -$3.49M | ﹤0.01% | 2004 |
|
|
2019
Q3 | $15.7M | Sell |
396,542
-33,867
| -8% | -$1.47M | ﹤0.01% | 1976 |
|
|
2019
Q2 | $17.7M | Sell |
430,409
-30,532
| -7% | -$1.26M | 0.01% | 1949 |
|
|
2019
Q1 | $21.5M | Buy |
460,941
+203,799
| +79% | +$8.95M | 0.01% | 1802 |
|
|
2018
Q4 | $11.2M | Sell |
257,142
-202,869
| -44% | -$10.1M | ﹤0.01% | 2268 |
|
|
2018
Q3 | $26.3M | Sell |
460,011
-80,869
| -15% | -$3.97M | 0.01% | 1716 |
|
|
2018
Q2 | $26.2M | Sell |
540,880
-14,139
| -3% | -$515K | 0.01% | 1686 |
|
|
2018
Q1 | $21.7M | Sell |
555,019
-54,962
| -9% | -$2.34M | 0.01% | 1794 |
|
|
2017
Q4 | $25.9M | Sell |
609,981
-22,700
| -4% | -$851K | 0.01% | 1744 |
|
|
2017
Q3 | $23.6M | Buy |
632,681
+112,624
| +22% | +$3.91M | 0.01% | 1850 |
|
|
2017
Q2 | $15.8M | Buy |
520,057
+16,618
| +3% | +$482K | ﹤0.01% | 2135 |
|
|
2017
Q1 | $13.3M | Buy |
503,439
+29,634
| +6% | +$781K | ﹤0.01% | 2191 |
|
|
2016
Q4 | $12.1M | Sell |
473,805
-361,578
| -43% | -$11.5M | ﹤0.01% | 2316 |
|
|
2016
Q3 | $30.2M | Buy |
835,383
+418,509
| +100% | +$13.9M | 0.01% | 1594 |
|
|
2016
Q2 | $14.2M | Buy |
416,874
+199,547
| +92% | +$6.49M | ﹤0.01% | 2059 |
|
|
2016
Q1 | $5.74M | Buy |
217,327
+200,946
| +1,227% | +$5.84M | ﹤0.01% | 2624 |
|
|
2015
Q4 | $799K | Buy |
16,381
+6,545
| +67% | +$236K | ﹤0.01% | 4510 |
|
|
2015
Q3 | $245K | Sell |
9,836
-18,804
| -66% | -$565K | ﹤0.01% | 5801 |
|
|
2015
Q2 | $906K | Buy |
28,640
+17,388
| +155% | +$561K | ﹤0.01% | 4625 |
|
|
2015
Q1 | $428K | Sell |
11,252
-5,147
| -31% | -$205K | ﹤0.01% | 5292 |
|
|
2014
Q4 | $639K | Buy |
+16,399
| New | +$572K | ﹤0.01% | 5056 |
|
Goldman Sachs's XLRN Position: Q4 2021 in Review
Goldman Sachs sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 418,302 shares — an estimated $72M sold.
Goldman Sachs first reported a position in XLRN in Q4 2014 and held it in 28 quarters. The position peaked at $72M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Goldman Sachs reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Goldman Sachs sold 418,302 Acceleron Pharma shares in Q4 2021, an estimated $72M.
- Goldman Sachs first reported a position in Acceleron Pharma in Q4 2014 and held it in 28 quarters.
- Goldman Sachs's Acceleron Pharma position peaked at $72M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.